Register | Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC

Specialties >>

AML
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
CLL
Colorectal Cancer
DLBCL
EGFR+ Lung Cancer
Follicular Lymphoma
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancers
HCC
Head & Neck Cancers
Hematology
HER2-Negative Breast Cancer
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
MPNs
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Sarcoma
Skin Cancers
Thyroid Cancers

Partners >>

Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up

Targeted Therapies in Oncology
December 2018

Clinical Articles

Glioblastoma Expert Calls for Changes to Clinical Trial Design
Overcoming Resistance to Immunotherapy Requires Advanced Strategies
Conventional Views May Not Apply to All Triple-Negative Breast Cancers
Promise Is Seen in Newer EGFR TKIs to Overcome Resistance in NSCLC
New Approvals in 2018 Change NCCN Guidelines for Hematologic Malignancies
MRD Could See More Use as Biomarker or Endpoint in the Future, FDA Says
Turning the Tide on Opioid Prescribing Practices
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.